Results
A total of 241 patients (109 female, 132 male) were included in the study. Of the patients (n = 241), 56.01% (n = 135) were in the ROSC group and 43.98% (n = 106) were in the non-ROSC group. There were no statistically significant differences in age and gender between the ROSC and non-ROSC groups (Table I).
CPR duration was 14.12 ± 11.67 min in the ROSC group, while it was 48.26 ± 10.61 min in the non-ROSC group, and the difference between them was statistically significant (p < 0.001). In terms of the initial arrest rhythm (Asystole, VF, VT, PEA); there was a statistically significant difference between the ROSC group (n = 91, 8, 3, and 21, respectively) and the non-ROSC group (n = 95, 0, 0, and 10, respectively) (p = 0.003).
When comparing the ROSC group and the non-ROSC group in terms of routine biochemistry and cardiac markers, the urea, creatinine, potassium, and cTn levels in the non-ROSC group (125.91 ± 88.71 mg dL-1, 2.47 ± 1.73 mg dL-1, 5.13 ± 1.33 mmol L-1, and 971.05 ± 2674.55 pg mL-1, respectively) were higher than the ROSC group (88.6 ± 65.08 mg dL-1, 1.87 ± 1.32 mg dL-1, 4.69 ± 1.29 mmol L-1, and 578.69 ± 1770.28 pg mL-1, respectively) and the differences between them were statistically significant (p < 0.001, 0.001, 0.014, and 0.005, respectively). There was no statistically significant difference between these groups in terms of other routine biochemistry and cardiac markers (Table II).
When comparing the ROSC group and the non-ROSC group in terms of blood gas parameters, the COHb level in the non-ROSC group (0.71 ± 0.57%) was lower than the COHb level in the ROSC group (0.95 ± 0.76%), and the difference between them was statistically significant (p = 0.002) (Table II). There was no statistically significant difference between these groups in terms of other blood gas parameters.
Of the patients who achieved ROSC and could be followed up (n = 78), 82.05% (n = 64) died (non-survivor group), and 17.95% (n = 14) were discharged from the hospital (survivor group). The mean age of the non-survivor group was 71.98 ± 11.95 years, while the mean age of the survivor group was 59.36 ± 20.96 years and the difference between them was statistically significant (p = 0.025). In terms of gender, there was no statistically significant difference between these groups (Table III).
The CPR duration was 17.17 ± 14.65 min in the non-survivor group, while it was 6.29 ± 2.84 min in the survivor group, and the difference between them was statistically significant (p < 0.001). In terms of the initial arrest rhythm (Asystole, VF, VT, PEA); there was a statistically significant difference between the non-survivor group (n = 45, 1, 1, and 7; respectively) and the survivor group (n = 5, 6, 0, and 2; respectively) (p < 0.001) (Table III).
When comparing the non-survivor group and the survivor group in terms of routine biochemistry and cardiac markers, the urea, creatinine, potassium, lactate dehydrogenase (LDH), and cTn levels in the non-survivor group (91.51 ± 58.06 mg dL-1, 2.08 ± 1.64 mg dL-1, 4.93 ± 1.22 mmol L-1, 1072.14 ± 3119.52 U L-1, and 685.39 ± 1687.14 pg mL-1, respectively) were higher than in the survivor group (40.62 ± 20.49 mg dL-1, 1.09 ± 0.49 mg dL-1, 3.60 ± 0.68 mmol L-1, 282.44±76.02, and 62.30 ± 115.67 pg mL-1, respectively) and the differences between them were statistically significant (p = 0.001, 0.005, 0.001, 0.010, and 0.008, respectively). There was no statistically significant difference between these groups in terms of other parameters (Table IV).
When comparing the non-survivor and survivor groups in terms of blood gas parameters, the COHb, bicarbonate (HCO3) and tCO2 levels in the non-survivor group (0.78 ± 0.53%, 15.44 ± 5.62 mmol L-1, and 34.64 ± 12.36 mmol L-1, respectively) were lower than survivor group (1.45 ± 1.31%, 20.14 ± 5.84 mmol L-1, and 44.76 ± 13.15, respectively), and the difference between them was statistically significant (p = 0.022, 0.016, and 0.017, respectively). There was no statistically significant difference between these groups in terms of other blood gas parameters (Table IV).